Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-243

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 243 52)

Label for Valsartan and Hydrochlorothiazide tablets USP, 320 mg / 25 mg strength. The package contains 30 film-coated tablets by Northwind Pharmaceuticals Inc., repackaged by Northwind Health Company, LLC. Stored at controlled room temperature (20°-25°C), with instructions to keep out of reach of children and protect from moisture and heat.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)

A line graph depicting the percentage of patients with systolic blood pressure (SBP) below 140 mmHg, plotted against baseline SBP values ranging from 140 to 180 mmHg. Four treatment groups are shown: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with Valsartan and Hydrochlorothiazide 320/25 mg consistently achieving the highest percentage below SBP 140.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)

A line graph depicting the percent of diastolic blood pressure (DBP) less than 90 mmHg versus baseline DBP in mmHg for four treatment groups: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. Each group is marked by distinct symbols showing trends across a baseline DBP range of 90 to 110 mmHg.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)

A line graph displaying the percentage of patients with systolic blood pressure (SBP) less than 130 mmHg versus their baseline SBP (mmHg). It compares four groups: valsartan and hydrochlorothiazide 320/25 mg (solid circles), valsartan 320 mg (open triangles), hydrochlorothiazide 25 mg (open squares), and placebo (crosses). The combined treatment shows the highest percentage of patients achieving SBP below 130 mmHg across the baseline range.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)

A line graph showing the percentage decrease in diastolic blood pressure (DBP-80) versus baseline diastolic blood pressure (mmHg). The graph compares four groups: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, represented by different symbols. Data points show trends of DBP reduction across baseline values from 90 to 110 mmHg.*

FDA Label Image

Valsartan Structural Formula (Image 05)

Chemical structure diagram of valsartan, one of the active ingredients in the Valsartan and Hydrochlorothiazide oral tablet combination.*

FDA Label Image

Hydrochlorothiazide Structural Formula (Image 06)

Chemical structure of valsartan, showing its molecular framework with sulfonamide, chlorine, and nitrogen-containing groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.